Opdualag (80 mg Relatlimab / 240 mg Nivolumab pro 20 ml), Konzentrat zur Herstellung einer Infusionslösung
7680686090019
CH-68609
Konzentrat
Associated product:
OPDUALAG conc perf flac 20 ml
1 / 3
google
Article details
- Package size
- 1
- Selling units
- 1
- Measure
- Durchstechflasche(n)
- Galenic form
- Konzentrat
- Galenic group
- Tinkturen/Desinfektion
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
relatlimabum
|
80.0 MG | Substance | Wirkstoff (Principe actif) |
|
nivolumabum
|
240.0 MG | Substance | Wirkstoff (Principe actif) |
|
histidinum
|
- | Substance | HNIDK |
|
histidini hydrochloridum monohydricum
|
- | Substance | HNIDK |
|
saccharum
|
- | Substance | HNIDK |
|
polysorbatum 80
|
- | Substance | HNIDK |
|
acidum penteticum
|
- | Substance | HNIDK |
|
aqua ad iniectabile
|
- | Substance | HNIDK |
Reimbursement information
Public price
CHF 5960.15
Specialties list
Yes
Generic
No
Reimbursement limitation
SL addition date:
01/02/2024
Authorization holder
Bristol-Myers Squibb SA
6312 Steinhausen
Authorization information
- Swissmedic authorization number
- 68609
- Drug name
- Opdualag, Konzentrat zur Herstellung einer Infusionslösung
- Galenic form
- KOINF
- ATC Code
- L01FY02
- Authorization status
- Z
- Dispensing category
- A
- First authorization
- 23/12/2022
- Authorization expiration date
- 22/12/2027
- IT Number
- 07.16.1.
- Domain
- Human medicine
Package details
- Description (FR)
- OPDUALAG conc perf flac 20 ml
- Description (DE)
- OPDUALAG Inf Konz Durchstf 20 ml
- Market launch
- 23/12/2022
- Narcotic (BTM)
- No